Clinical Trials
31 trialsNCT07287150 2026-06-04
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT07190300 2026-06-03
TulmiSTAR-02
Novartis
Phase 1/2 Recruiting
NCT07226986 2026-06-03
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
NCT06991556 2026-06-02
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT04221542 2026-05-29
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT06863272 2026-05-29
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07570979 2026-05-28
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Phase 1 Recruiting
NCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06952803 2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT06691984 2026-05-15
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Active not recruiting
NCT03644303 2026-05-14
TRAP
Royal Marsden NHS Foundation Trust
Phase NA Completed
NCT04262154 2026-05-11
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT07140900 2026-05-05
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
Phase 1 Recruiting
NCT05177042 2026-04-28
Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer
Arvinas Inc.
Phase 1 Completed
NCT07553988 2026-04-28
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
R-Pharm
Phase 2 Active not recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04787744 2026-04-08
VA STARPORT
VA Office of Research and Development
Phase 2/3 Recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06832774 2026-03-25
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06421935 2026-03-24
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono
Phase 1 Active not recruiting
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting